Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This project has the following primary aims:
The main objective is to delineate the association between changes in Resting energy expenditure (REE) and QOL in hypothyroid patients before and after one year of L-T4 treatment. To achieve this, the investigators plan to compare newly diagnosed hypothyroid patients soon after diagnosis before L-T4 therapy has been initiated after 6 months and after 1 year of treatment.
Primary endpoint is changes in REE compared to changes in QOL Secondary endpoint is changes in cognitive function and changes in body composition before and after one year of treatment and furthermore changes in insulin resistance following changes in body composition and free fatty acids (FFA).
Subjects and Methods:
74 newly diagnosed hypothyroid patients of both genders and age between 20 and 75 years will be recruited from the out-patients clinic in Herlev and Gentofte Hospital and the general practitioners before start of substitution therapy. Participants will get an appointment immediately after diagnosis to avoid unnecessary delay of treatment. Shortly after diagnosis patients will undergo a test panel at the first experimental day, where patients arrives fasting.
Psychological test using:
REE will be measured by a CCM-express calorimeter,
DEXA-scan
Blood samples will be taken and patients will be characterized through basic information.
Insulin resistance will be assess through an oral glucose tolerance test (OGTT) At end of the first experimental day patients will start L-T4 therapy following national guidelines, with regular control of thyroid hormones to ensure optimal treatment. When patients are euthyroid and TSH is below 4 * 10-3 International Units pr liter (mU/l) patients will have blood samples monitored every 3 months for the rest of the trial.
After 6 and 12 months of treatment patients will undergo a similar experimental day and return to their general practitioner or outpatient clinic.
A control group of 18 matched healthy persons will undergo the first experimental day in the same way as the hypothyroid patients, except they do not start any kind of therapy and they only participate in the first experimental day.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hypothyroid | Levothyroxine treatment |
| |
| Healthy volunteers | Matched on age and BMI 18 persons |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Levothyroxine treatment | Drug | Eltroxin/Euthyrox is part of the normal treatment for hypothyroidism, and the patient is treated equally, whether he/she participates or not. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes in quality of life as measured with the ThyPro questionaire | 1 year | |
| Changes in resting energy expenditure in KCal/day | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Perceived Deficit Questionaire | 1 year | |
| Changes in insulin resistance evaluated by MATSUDA index | 1 year | |
| Changes in insulin resistance evaluated by HOMA index |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Hypothyroid patients.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bjarke Medici, MD | Bjarke Medici | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of internal Medicine, Herlev Hospital | Herlev | Capital Region | DK-2730 | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34194721 | Derived | Medici BB, Lerche la Cour J, Knop FK, Krakauer M, Michaelsson LF, Faber J, Watt T, Nygaard B. Predictors of Improvement in Quality of Life When Treating Hypothyroidism. J Thyroid Res. 2021 Jun 11;2021:5577217. doi: 10.1155/2021/5577217. eCollection 2021. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007037 | Hypothyroidism |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D013959 | Thyroid Diseases |
| D004700 | Endocrine System Diseases |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D013974 | Thyroxine |
| ID | Term |
|---|---|
| D013963 | Thyroid Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D024322 | Amino Acids, Aromatic |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood
|
| 1 year |
| Changes in cognitive tests | 1 year |
| Changes in body composition asses through lean mass | 1 year |
| Changes in body composition asses through visceral adipose tissue | 1 year |
| Changes in body composition asses through fat mass | 1 year |
| Changes in free fatty acids | 1 year |
| Changes in cholesterol | 1 year |
| Changes in serum triglycerides | 1 year |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D000598 | Amino Acids, Cyclic |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |